SCHEMBL4422582

SCHEMBL4422582

COc1cccc2c1[nH]c1ncc(C)cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.59
PDK4 Q16654 1/20 0.59
NQO2 P16083 1/20 0.49
KDM4E B2RXH2 3/20 0.44
GAA P10253 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
MCL1 Q07820 2/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GLA P06280 1/20 0.44
UTS2R Q9UKP6 1/20 0.43
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415544 0.84 NQO2 (0.44) PDK2PDK4NQO2KDM4EGAA
SCHEMBL4412776 0.81 PDK2 (0.65) PDK2PDK4GAAALDH1A1HPGD
SCHEMBL13596953 0.79 NQO2 (0.49) PDK2PDK4NQO2KDM4EGAA
SCHEMBL3942114 0.79 PDK2 (0.62) PDK2PDK4KDM4E
SCHEMBL4414051 0.79 PDK2 (0.62) PDK2PDK4
SCHEMBL3942295 0.79 PDK2 (0.49) PDK2PDK4NQO2KDM4E
SCHEMBL4422523 0.78 PDK2 (0.53) PDK2NQO2KDM4EGAAALDH1A1
SCHEMBL12955038 0.78 NQO2 (0.43) PDK2PDK4NQO2KDM4EGAA
SCHEMBL29567609 0.78 KDM4E (0.46) NQO2KDM4EGAAALDH1A1HPGD
SCHEMBL4420604 0.77 PDK2 (0.59) PDK2PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326229-A1 ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF XDH, F7, CYP4X1 PDK2 178/4885PDK4 212/4885NQO2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.